Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945243 | 0.90 | PTGS1 (0.57) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL26116358 | 0.87 | PTGS1 (0.57) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL2952502 | 0.86 | PTGS1 (0.57) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL26571353 | 0.86 | SLC2A1 (0.58) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL497922 | 0.86 | CA12 (0.58) | PTGS1LMNAEGFRERN1CA1 | |
| SCHEMBL2941838 | 0.84 | PTGS1 (0.55) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL2946107 | 0.84 | PTGS1 (0.55) | PTGS1NPC1RAB9AMAPTLMNA | |
| SCHEMBL21838886 | 0.84 | EGFR (0.51) | PTGS1EGFRMAP2K4SLC6A3ERN1 | |
| SCHEMBL26115204 | 0.84 | EGFR (0.51) | PTGS1MAPTEGFRMAP2K4MEN1 | |
| SCHEMBL26572470 | 0.84 | PTGS1 (0.55) | PTGS1NPC1RAB9AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut (DE) | 2022-11-01 | — | — | US | disclosed |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2020-10-29 | — | — | US | disclosed |
| WO-2019101679-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V. HANS-KNÖLL INSTITUT (HKI) (DE) | 2019-05-31 | — | — | WO | disclosed |
| EP-3486229-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- (HKI) (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-1436249-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1644320-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608617-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005009941-A1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| WO-2004094363-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1436249-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003027061-A2 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242584-A1 | exemplified by Biphenyl-4-carboxylic acid (R)-(6-(1-((4-fluorobenzyl)methylamino)ethylideneamino) 2(R)-hydroxyindan-1-yl)amide; treating cognitive impairment associated with schizophrenia or Alzheimer's disease | CHRM1, CHRM2, CHRM4 | PTGS1 1799/4885NPC1 1258/4885RAB9A 1336/4885 |
| US-11485721-B2 | Method for the metal-free preparation of a biaryl by a photosplicing reaction and their uses | CBR3, POR, CYP2F1 | PTGS1 1202/4885NPC1 4271/4885RAB9A 2172/4885 |
| US-20200339529-A1 | METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES | CBR3, POR, CYP2F1 | PTGS1 1202/4885NPC1 4271/4885RAB9A 2172/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PTGS1 1160/4885NPC1 95/4885RAB9A 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.